Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14983992 | 1.00 | ABCB1 (0.32) | ABCB1CYP1A2CYP2C19 | |
| SCHEMBL15604384 | 1.00 | ABCB1 (0.32) | ABCB1CYP1A2CYP2C19 | |
| SCHEMBL17083027 | 1.00 | ABCB1 (0.32) | ABCB1CYP1A2CYP2C19 | |
| SCHEMBL14983997 | 1.00 | ABCB1 (0.32) | ABCB1CYP1A2CYP2C19 | |
| SCHEMBL23416462 | 0.93 | ABCB1 (0.32) | ABCB1CYP1A2CYP2C19 | |
| SCHEMBL16247231 | 0.93 | ABCB1 (0.32) | ABCB1CYP1A2CYP2C19 | |
| SCHEMBL19660999 | 0.93 | ABCB1 (0.32) | ABCB1CYP1A2CYP2C19 | |
| SCHEMBL19455910 | 0.93 | ABCB1 (0.32) | ABCB1CYP1A2CYP2C19 | |
| SCHEMBL18481586 | 0.91 | ABCB1 (0.31) | ABCB1 | |
| SCHEMBL19844434 | 0.90 | ABCB1 (0.31) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9636413-B2 | Conjugates for treating diseases caused by PSMA expressing cells | ENDOCYTE, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (US) | 2016-12-15 | — | — | US | disclosed |
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE INC (IN) | 2016-12-15 | — | — | US | disclosed |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | ENDOCYTE, INC. | 2015-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361432-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | ABCB1 411/4885CYP1A2 4453/4885CYP2C19 4553/4885 |
| US-20160361433-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | ABCB1 411/4885CYP1A2 4453/4885CYP2C19 4553/4885 |
| US-20150297735-A1 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | FOLH1, KLK3, CD47 | ABCB1 411/4885CYP1A2 4453/4885CYP2C19 4553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.